X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Liralin (linagliptin) is a DPP-4 (Dipeptidyl peptidase IV) inhibitor, oral small molecule drug which is approved for the treatment of type-2-diabetes mellitus.
Lead Product(s): Linagliptin
Therapeutic Area: Endocrinology Product Name: Liralin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2023
Details:
Through the acquisition, Lupin expands its diabetes portfolio in India by gaining access to Ondero (linagliptin) and Ondero Met (linagliptin & metformin). Ondero is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes.
Lead Product(s): Linagliptin
Therapeutic Area: Endocrinology Product Name: Ondero
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: $28.3 million Upfront Cash: $28.3 million
Deal Type: Acquisition August 18, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
USV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
